Home › Research › Risk genes beyond APOE
Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration
Seyyed Hani Moussavi Nik, Tenielle Porter, Morgan Newman, Benjamin Bartlett, Imran Khan, Miheer Sabale, Melissa Eccles, Amy Woodfield et al.. Journal of Alzheimer's disease : JAD, 2021
Topic: Genetics and APOE
Plain-language summary
PS2V levels increased in AD postmortem brain but PS2V was also present at significant levels in FTD and LBD brains. PS2V transcript was detected in lymphocytes and PS2V/PSEN2 ratios were increased in mild cognitive impairment (p = 0.024) and AD (p = 0.019) groups compared to control group. Increased ratios were significantly correlated with hippocampal volumes only (n = 62, β= -0.269, p = 0.03). Taken together, these results suggest that PS2V may be a marker of overall neurodegeneration.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nik, S. H. M., Porter, T., Newman, M., Bartlett, B., Khan, I., Sabale, M., et al. (2021). Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-201133
Vancouver
Nik SHM, Porter T, Newman M, Bartlett B, Khan I, Sabale M, et al. Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. Journal of Alzheimer's disease : JAD. 2021. doi:10.3233/jad-201133. PMID: 33720885.
BibTeX
@article{nik2021-33720885,
author = {Nik, Seyyed Hani Moussavi and Porter, Tenielle and Newman, Morgan and Bartlett, Benjamin and Khan, Imran and Sabale, Miheer and Eccles, Melissa and Woodfield, Amy and others},
title = {{Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2021},
doi = {10.3233/jad-201133},
pmid = {33720885},
url = {https://doi.org/10.3233/jad-201133}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- PS2V levels increased in AD postmortem brain but PS2V was also present at significant levels in FTD and LBD brains.
- PS2V transcript was detected in lymphocytes and PS2V/PSEN2 ratios were increased in mild cognitive impairment (p = 0.024) and AD (p = 0.019) groups compared to control group.
- Increased ratios were significantly correlated with hippocampal volumes only (n = 62, β= -0.269, p = 0.03).
- Taken together, these results suggest that PS2V may be a marker of overall neurodegeneration.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Participants160
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 28 of the 56 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 160 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33720885) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 28 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 28 of the 56 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk genes beyond APOE from nearby years
Also tagged “single-nucleus”
274 studies in the library carry the topic tag “single-nucleus”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 274 tagged studies.